The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 clinical trial results for NG-350A, a novel transgene-armed and tumor-selective vector: Differential effects of intravenous (IV) versus intratumoral (IT) dosing on immune pharmacodynamics (PD).
 
Minesh Patel
Employment - Akamis Bio
Stock and Other Ownership Interests - Akamis Bio
 
Chris Cox
Employment - Akamis Bio
Stock and Other Ownership Interests - Akamis Bio
 
David Krige
Employment - Accession Therapeutics; Akamis Bio
Stock and Other Ownership Interests - Accession Therapeutics; Akamis Bio
 
Lyle Walker
Employment - Akamis Bio
Stock and Other Ownership Interests - Akamis Bio
 
Vladimir Evilevitch
Employment - Akamis Bio
Stock and Other Ownership Interests - Akamis Bio
 
Jo Carter
Employment - Akamis Bio
Stock and Other Ownership Interests - Akamis Bio
 
Matthew Thomas
Employment - Akamis Bio
Stock and Other Ownership Interests - Akamis Bio
 
Samantha Bucktrout
Employment - Akamis Bio
Stock and Other Ownership Interests - Akamis Bio
 
Brian Champion
Employment - Akamis Bio
Leadership - Akamis Bio
Stock and Other Ownership Interests - Akamis Bio
 
Thomas Lillie
Employment - PsiOxus Therapeutics
Leadership - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Lee S. Rosen
Research Funding - Akamis Bio; Bayer; Pfizer; Rgenix
 
Aung Naing
Employment - MD Anderson Cancer Center
Honoraria - AKH Inc.; American Society of Clinical Oncology; CME Outfitters; ESMO; Korean Society of Medical Oncology (KSMO); Lynx Group; Scripps Hospital; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Abbvie; CytomX Therapeutics; Deka Biosciences; Genome & Company; Horizon Therapeutics (I); Immune-Onc Therapeutics; Lynx Health; Merk Sharp & Dohme Corp; NGM Biopharmaceuticals; Nouscom; OncoNano Inc; OncoSec; Pharming NV (I); PsiOxus Therapeutics; PsiOxus Therapeutics; SERVIER; STCube Pharmaceuticals Inc.; Takeda (I)
Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; Baxalta (I); BioNTech SE; Bristol-Myers Squibb; Calithera Biosciences; Chao Physician-Scientist Awards (I); CytomX Therapeutics; EMD Serono; Healios; Immune Deficiency Foundation (I); ImmuneOncia; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; Monopteros Therapeutics; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Seven and Eight Biopharmaceuticals; Sotio; Surface Oncology; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences; NeoImmuneTech; NGM Biopharmaceuticals